A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
Status:
Completed
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the amount of linaclotide and its active metabolite
(MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (72 μg,
145 μg, or 290 μg) in lactating women receiving the drug therapeutically.